


Group III consisted of claims 17-21, stated by the Examiner as drawn to a method of treating fungal infections.

Applicants respectfully traverse the Examiner's restriction requirement in view of U.S. Patent Nos. 5,858,974 and 6,156,730, wherein Applicants' claims to antifungal peptides, to methods for killing or inhibiting replication of fungi with those antifungal peptides, and to methods for treating fungal infections with those antifungal peptides were not considered to be distinct, they were not considered to have acquired a separate status in the art as a separate subject for inventive effect, and they did not require independent searches. Rather, the claims were searched, examined and issued together without restriction. Thus, Applicants respectfully request withdrawal of the restriction requirement and examination of pending related claims 1-21.

Applicants' election of Group I, claims 1-15 is hereby made without prejudice to Applicants' right to pursue the non-elected claims in one or more divisional applications. The Examiner is invited to telephone Applicants' representative if the Examiner believes, for any reason, that personal communication would expedite the prosecution of this application.

Respectfully submitted,

Date: August 12, 2003

  
\_\_\_\_\_  
Janet M. McNicholas, Ph.D.  
Registration No. 32,918

McAndrews, Held & Malloy, Ltd.  
500 West Madison Street, 34<sup>th</sup> Floor  
Chicago, Illinois 60661  
Telephone: (312) 775-8000  
Facsimile: (312) 775-8100